C. N. Harrison, « Ruxolitinib vs Best Available Therapy for ET Intolerant or Resistant to Hydroxycarbamide, Blood, vol.130, pp.1889-97

J. Berdeja, Phase 2 Study of Gandotinib (LY2784544) in Patients with Myeloproliferative Neoplasms », vol.71, pp.82-88, 2018.

. Tefferi, The Clinical Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2V617F in Polycythemia Vera, vol.3, pp.631-635, 2006.

. Vannuchi, Prospective Identification of High-Risk Polycythemia Vera Patients Based on JAK2V617F Allele Burden, vol.21, pp.1952-59, 2007.